Pursuing a fully closed cellular immunotherapy manufacturing model

Cell & Gene Therapy Insights 2021; 7(5), 627–636


Published: 8 June 2021
Ed Samuel

Ed Samuel serves as SVP Technical Operations at Achilles with responsibility for overseeing GMP operations for product delivery of its autologous T cell therapies, the expansion of the Achilles manufacturing footprint and the integration of automation and device technology driving the future platform for commercial delivery. Ed has over 18 years of industry and academic experience in process development, technology transfer, GMP manufacturing, QC and regulatory affairs in the field of cell and gene therapy. Before joining Achilles in December 2017, Ed was the Cell Therapy Operations Manager for Europe at Orchard Therapeutics where he was responsible for overseeing CDMO tech transfer and establishing the supply-chain infrastructure to support cell therapy manufacturing and regulatory submissions in the US and Europe. Previously, Ed held positions at Cognate BioServices Ltd as Director for Manufacturing and in post-doctoral translational research at University College London (UCL). Ed holds a PhD in T cell Immunology from UCL, and an MSc in Medical Immunology from King’s College London.